Pay in 4 interest-free payments of $5.02 Learn more
Ships within 48 hours · Estimated delivery Oct 17 - Oct 22
SURMOUNT-1 The SURMOUNT-1 study in obese patients without diabetes showed that tirzepatide met two co-primary endpoints
These changes arent listed in Ozempics official prescribing information but are thought to happen when fat volume in certain areas drops quickly
Evidence from SURPASS CVOT is awaited to assess whether these benefits on surrogate markers will translate into actual MACE prevention
The analyte then disperses into the extraction phase, where it diffuses through the extraction medium and enters the region where convection occurs
CVOTs specifically evaluate the incidence of major adverse cardiovascular events (MACE), which includes CV mortality, non-fatal myocardial infarction, and non-fatal stroke, commonly known as 3-point MACE. Hospitalization for acute coronary syndrome, urgent revascularization procedures, and other possible endpoints such as hospitalization for angina or HF can also be incorporated into the CV outcome endpoints of interest
US$ 25.23
US$ 29.16
US$ 26.68
US$ 27.97
US$ 28.91
